United Therapeutics director exercises 1,000 options and sells shares

United Therapeutics Corporation director reports stock option exercise and share sale.

Rhea-AI Filing Summary

United Therapeutics Corporation director reports stock option exercise and share sale. On 12/15/2025, the reporting person exercised 1,000 stock options at an exercise price of $101.80 per share and acquired an equal number of United Therapeutics common shares. On the same date, they sold 1,000 shares of common stock at a weighted average price of $495.9539 per share, with individual trades executed between $495.64 and $496.09. Following these transactions, the director beneficially owns 1,490 shares directly and 1,100 shares indirectly through a trust, as well as 3,910 stock options with a $101.80 exercise price expiring on 06/21/2026.

Insider Trade Summary

Exercise and Sale: 1,000 shares ($394K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider PATUSKY CHRISTOPHER

Role Director

Sold 1,000 shs ($496K)

Approx. gross sale proceeds $496K

Approx. exercise cost $102K

Approx. pre-tax spread $394K

Type	Security	Shares	Price	Value
Exercise	Stock Option	1,000	$0.00	$0.00
Exercise	Common Stock	1,000	$101.80	$102K
Sale	Common Stock	1,000	$495.9539	$496K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option — 3,910 contracts (Direct); Common Stock — 1,490 shares (Direct); Common Stock — 1,100 shares (Indirect, by Trust)

Footnotes (1)

1. F1. This transaction was executed in multiple trades at prices ranging from $495.64 to $496.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock transactions did United Therapeutics (UTHR) report on this Form 4?

A United Therapeutics director reported exercising 1,000 stock options at an exercise price of $101.80 per share and selling 1,000 shares of common stock at a weighted average price of $495.9539 per share on 12/15/2025.

What is the transaction date on the United Therapeutics (UTHR) Form 4 filing?

The earliest reported transaction date is 12/15/2025, covering both the stock option exercise and the sale of common shares.

How many United Therapeutics (UTHR) shares does the director own after the reported transactions?

After the reported transactions, the director beneficially owns 2,490 shares of United Therapeutics common stock directly and 1,100 shares indirectly through a trust.

What derivative securities related to United Therapeutics (UTHR) does the director still hold?

The director holds 3,910 stock options with an exercise price of $101.80 per share, each option covering United Therapeutics common stock and expiring on 06/21/2026.

What price range did the United Therapeutics (UTHR) share sale cover on 12/15/2025?

The reported sale of 1,000 shares on 12/15/2025 was executed in multiple trades at prices ranging from $495.64 to $496.09 per share, with a weighted average price of $495.9539.

Is the reporting person a director or officer of United Therapeutics (UTHR)?

The reporting person is identified as a director of United Therapeutics Corporation on the form.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/16/2025 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PATUSKY CHRISTOPHER

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2025		M		1,000	A	$101.8	2,490	D
Common Stock	12/15/2025		S		1,000	D	$495.9539(1)	1,490	D
Common Stock								1,100	I	by Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$101.8	12/15/2025		M			1,000	06/21/2017	06/21/2026	Common Stock	1,000	$0.00	3,910	D

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $495.64 to $496.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.